|
|
Article: CIMA LABS Announces FDA Approval Of Additional Dosage Form of AstraZeneca's Zomig-ZMT.
- Article from:
- Business Wire
- Article date:
- September 20, 2001
CopyrightCOPYRIGHT 2001 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors & Health/Medical Writers
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Sept. 20, 2001
CIMA LABS INC. (Nasdaq:CIMA) today announced that the Food and Drug Administration (FDA) has issued U.S. marketing approval for a 5.0 mg dosage form of Zomig-ZMT(TM) (zolmitriptan). CIMA developed this 5.0 mg fast-dissolve dosage form for AstraZeneca (NYSE:AZN) as a complementary product to the 2.5 mg dosage form of Zomig-ZMT that was launched in the U.S. market earlier this year.
Zomig-ZMT, an orally disintegrating compound incorporating CIMA's DuraSolv(TM) fast-dissolve drug delivery system with AstraZeneca's active drug ingredient zolmitriptan, is ...